PHS
VRTX icon

Pekin Hardy Strauss’s Vertex Pharmaceuticals VRTX Stock Holding History

Pekin Hardy Strauss’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,106
Closed -$433K – 481
2025
Q3 		$433K Buy
+1,106
New +$462K 0.04% 274

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Pekin Hardy Strauss's VRTX Position: Q4 2025 in Review

Pekin Hardy Strauss sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 1,106 shares — an estimated $433K sold.

Pekin Hardy Strauss first reported a position in VRTX in Q3 2025 and held it in 1 quarter. The position peaked at $433K in Q3 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Pekin Hardy Strauss reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Pekin Hardy Strauss sold 1,106 Vertex Pharmaceuticals shares in Q4 2025, an estimated $433K.
  • Pekin Hardy Strauss first reported a position in Vertex Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Pekin Hardy Strauss's Vertex Pharmaceuticals position peaked at $433K in Q3 2025.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Pekin Hardy Strauss's 13F filing for Q4 2025, filed 30 Jan 2026.